Live Breaking News & Updates on Tumors

Stay informed with the latest breaking news from Tumors on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Tumors and stay connected to the pulse of your community

HER2+ Breast Cancer Treatment Dynamics and Challenges

Health care professionals discuss the evolving landscape of HER2+ breast cancer treatments, delving into the complexities of the HER2CLIMB trial and strategies for third- and fourth-line interventions.

Joyce-oshaughnessy , Heather-mcarthur , Priyanka-sharma , Claudine-isaacs , Peer-exchange , Joyceo-shaughnessy , Patients , Positive , Tumors , Neoadjuvant , Adjuvant-setting , Disease

Decoding HER2+ Breast Cancer: Challenges in Brain Metastases

Experts explore the intricacies of managing brain metastases in HER2+ breast cancer and delve into the latest evidence, patient considerations, and evolving guidelines for this complex scenario.

Heather-mcarthur , Claudine-isaacs , Joyce-oshaughnessy , Priyanka-sharma , Peer-exchange , Joyceo-shaughnessy , Patients , Positive , Tumors , Neoadjuvant , Adjuvant-setting , Disease

Scholarship available for tumor survivors | The Riverdale Press

Making Headway is a nonprofit supporting families of children diagnosed with brain or spinal cord tumors. In 2024 the organization will provide up to 15 scholarships of up to $5,000 to eligible applications.

New-jersey , United-states , Hollins-university , Virginia , New-york , Connecticut , Florida-institute-of-technology , Florida , Isaiah-shikany , Matilda-sieger , James-magill , Elias-orellana

Exploring Therapeutic Avenues in HER2+ Breast Cancer

Experts delve into post–KATHERINE trial discussions, examining data and its impact on residual disease. They highlight unmet needs, emphasizing the ongoing CompassHER2 RD trial’s potential to address challenges, especially regarding brain metastases.

Heather-mcarthur , Joyce-oshaughnessy , Priyanka-sharma , Claudine-isaacs , Peer-exchange , Joyceo-shaughnessy , Patients , Positive , Tumors , Neoadjuvant , Adjuvant-setting , Disease

Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials

Experts discuss the CLEOPATRA trial outcomes, taxane nuances, and evolving strategies in first-line treatment. They review practical considerations and ongoing trials and dive into the dynamic landscape of managing metastatic HER2+ breast cancer, anticipating transformative developments.

Claudine-isaacs , Priyanka-sharma , Heather-mcarthur , Joyce-oshaughnessy , Translational-breast-cancer-research-consortium , Peer-exchange , Joyceo-shaughnessy , Patients , Positive , Tumors , Neoadjuvant , Adjuvant-setting

Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring

Health care professionals review considerations in transitioning breast cancer patients to the adjuvant setting and discuss response monitoring, treatment tailoring, and the evolving role of imaging.

Priyanka-sharma , Joyce-oshaughnessy , Heather-mcarthur , Claudine-isaacs , Peer-exchange , Joyceo-shaughnessy , Patients , Positive , Tumors , Neoadjuvant , Adjuvant-setting , Disease

Evolving Strategies in Adjuvant HER2+ Breast Cancer

Experts analyze adjuvant therapy based on preoperative responses. The discussion unveils standard practices, recent KATHERINE trial data, and considerations for residual disease, offering profound insights into tailoring treatment for improved outcomes.

Priyanka-sharma , Joyce-oshaughnessy , Heather-mcarthur , Claudine-isaacs , Peer-exchange , Joyceo-shaughnessy , Patients , Positive , Tumors , Neoadjuvant , Adjuvant-setting , Disease

Technion scientists predict efficacy of new cancer therapies

The researchers created a tool to predict which patients will respond to this therapy based on this therapy that shows the importance of metabolism in the tumor microenvironment.

Israel , Keren-yizhak , Haifa-technion , Israel-institute-of-technology , Technion-israel-institute , Ofir-shorer , Rappaport-faculty , Science , Scientific-study , Cancer-treatment , Immunotherapy , Tumors

Subcutaneous HER2+ Breast Cancer Treatment Trends

Experts discuss evolving practices in HER2+ breast cancer care, subcutaneous formulations, patient preferences, and resource conservation.

Breast-cancer , Applying-recent-data-updates , Clinical-practice , Breast-cancer-treatment , Patients , Positive , Tumors , Neoadjuvant , Adjuvant-setting , Disease , Regimen

HER2+ Breast Cancer: Anthracycline Considerations

Experts discuss anthracycline use in HER2+ breast cancer and provide insights into how patient scenarios, heterogeneity, and neuropathy concerns shape considerations in diverse clinical situations.

Breast-cancer , Applying-recent-data-updates , Clinical-practice , Patients , Positive , Tumors , Neoadjuvant , Adjuvant-setting , Disease , Regimen , Preoperative